What is Metavention?
Metavention is dedicated to pioneering treatments for high blood pressure through a distinctive renal denervation procedure. This method targets overactive sympathetic nerves using the iRF Denervation System, which employs radio frequency energy to disrupt these nerves. The company's approach aims not only to reduce blood pressure but also to potentially improve outcomes for patients with metabolic diseases. Metavention is committed to rigorous clinical studies to validate the safety and efficacy of its innovative therapy, striving to deliver life-changing treatments to a global patient and healthcare provider base.
How much funding has Metavention raised?
Metavention has raised a total of $42M across 2 funding rounds:
Series B
$12M
Series C
$30M
Series B (2014): $12M, investors not publicly disclosed
Series C (2017): $30M led by Versant Ventures, Sanderling Ventures, New Enterprise Associates, and Horowitz Group
Key Investors in Metavention
Versant Ventures
Versant Ventures is a venture capital firm specializing in building and funding innovative biotechnology companies globally. With extensive experience and significant capital under management, they focus on early-stage investments and have a strong history of successful IPOs and M&A transactions in the life sciences sector.
Sanderling Ventures
Sanderling Ventures is an early-stage investment firm with a long history in the biomedical sector, focusing on creating new companies and providing active management to achieve high returns. They invest across various areas including therapeutics, platform technologies, and medical devices.
New Enterprise Associates
New Enterprise Associates (NEA) is a prominent venture capital firm that partners with entrepreneurs to build transformative businesses. They have a broad investment focus across various technology and healthcare sectors, providing capital and strategic support to companies from inception through growth stages.
What's next for Metavention?
With substantial enterprise-level backing and a recent strategic investment, Metavention is poised for significant growth and advancement in the cardiovascular treatment space. The company's focus on clinical validation suggests a trajectory towards regulatory approval and commercialization. Future developments will likely involve expanding clinical trial participation, refining the iRF Denervation System based on trial data, and preparing for market entry. This strategic financing will be crucial in navigating the complex path from clinical research to widespread patient access, positioning Metavention as a key player in the interventional cardiology market.
See full Metavention company page
